Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Condition:   Pancreatic Cancer Interventions:   Drug: Atezolizumab;   Biological: RO7198457;   Drug: mFOLFIRINOX Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
(Queen Mary University of London) Researchers from Queen Mary University of London and Zhengzhou University have developed a personalised vaccine system that could ultimately delay the onset of pancreatic cancer. The study provides strong proof-of-concept for the creation of a vaccine for cancer prevention in individuals at high risk of developing this disease and to slow down tumour growth in patients who are affected by it.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: These results provide both proof of concept and a robust technology platform for personalized prophylactic cancer vaccines to prevent pancreatic malignancies in at-risk individuals. PMID: 31767564 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Condition:   Pancreatic Cancer Interventions:   Drug: Atezolizumab;   Biological: RO7198457;   Drug: mFOLFIRINOX Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pancreatic Adenocarcinoma;   Pancreatic Cancer Intervention:   Biological: Autologous DC vaccine Sponsors:   Baylor College of Medicine;   Cancer Cures for Kids Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Pancreas | Pancreatic Cancer | Research | Study | Vaccines